These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28870933)

  • 1. Clinicopathological Features of Ductal Carcinoma
    Fujii T; Yanai K; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Hirakata T; Kuwano H
    Anticancer Res; 2017 Sep; 37(9):5053-5056. PubMed ID: 28870933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the correlation between FDG PET findings of IDC breast carcinoma and histopathology of coexisting ductal carcinoma in-situ.
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Nucl Med Rev Cent East Eur; 2022; 25(1):6-11. PubMed ID: 35137931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
    Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
    Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy.
    Shigematsu H; Kadoya T; Masumoto N; Matsuura K; Emi A; Kajitani K; Amioka A; Okada M
    Clin Breast Cancer; 2014 Oct; 14(5):358-64. PubMed ID: 24962555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
    Fujii T; Yajima R; Kurozumi S; Higuchi T; Obayashi S; Tokiniwa H; Nagaoka R; Takata D; Horiguchi J; Kuwano H
    Anticancer Res; 2016 Oct; 36(10):5481-5485. PubMed ID: 27798919
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Mol Clin Oncol; 2017 Aug; 7(2):183-187. PubMed ID: 28781782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a difference in FDG PET findings of invasive ductal carcinoma of the breast with and without coexisting DCIS?
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Asia Ocean J Nucl Med Biol; 2020; 8(1):27-35. PubMed ID: 32064280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
    Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal carcinoma in situ: correlation between FDG-PET/CT and histopathology.
    Azuma A; Tozaki M; Ito K; Fukuma E; Tanaka T; O'uchi T
    Radiat Med; 2008 Oct; 26(8):488-93. PubMed ID: 18975050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.
    Yoon HJ; Kim Y; Kim BS
    Eur Radiol; 2015 Dec; 25(12):3648-58. PubMed ID: 26063655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.
    Fujii T; Yajima R; Tsuboi M; Higuchi T; Obayashi S; Tokiniwa H; Nagaoka R; Takata D; Horiguchi J; Kuwano H
    Anticancer Res; 2016 Jun; 36(6):3019-22. PubMed ID: 27272820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.
    Fujii T; Yanai K; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Hirakata T; Shirabe K
    Anticancer Res; 2018 Aug; 38(8):4927-4931. PubMed ID: 30061271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between reticuloendothelial systems' FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer.
    Şahin E; Elboğa U
    Radiol Med; 2017 Oct; 122(10):785-792. PubMed ID: 28597239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.
    Ito M; Shien T; Kaji M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Acta Med Okayama; 2015; 69(6):333-8. PubMed ID: 26690243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
    Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
    World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.